These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24398947)

  • 21. Pharmaceutical sciences in 2020.
    Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H
    Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959
    [No Abstract]   [Full Text] [Related]  

  • 22. The evolving role of collaboration in biotechnology.
    Gower JM
    Nat Biotechnol; 1998 May; 16 Suppl():31-2. PubMed ID: 9591261
    [No Abstract]   [Full Text] [Related]  

  • 23. [The common future of urology and the pharmaceutical industry].
    Odenthal G
    Urologe A; 2006 Sep; 45 Suppl 4():41-3. PubMed ID: 16955325
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical drug research in German urology from the viewpoint of a sponsor].
    Burkart M
    Urologe A; 2006 Sep; 45 Suppl 4():45-7. PubMed ID: 16832641
    [No Abstract]   [Full Text] [Related]  

  • 25. The NIH, research institutions and industry: working together on a shared goal.
    Omary MB
    Gastroenterology; 2007 May; 132(5):1647-50. PubMed ID: 17484859
    [No Abstract]   [Full Text] [Related]  

  • 26. Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field.
    Sanson-Fisher R; Brand M; Shakeshaft A; Haber P; Day C; Conigrave K; Mattick R; Lintzeris N; Teesson M
    Drug Alcohol Rev; 2010 Sep; 29(5):469-74. PubMed ID: 20887569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paving the critical path: how can clinical pharmacology help achieve the vision?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):170-7. PubMed ID: 17259944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of simulation to compare the performance of minimization with stratified blocked randomization.
    Toorawa R; Adena M; Donovan M; Jones S; Conlon J
    Pharm Stat; 2009; 8(4):264-78. PubMed ID: 18756580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2011 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
    [No Abstract]   [Full Text] [Related]  

  • 30. Restructurally sound.
    Borrell B
    Nat Med; 2011 May; 17(5):531-3. PubMed ID: 21546961
    [No Abstract]   [Full Text] [Related]  

  • 31. Paul Brown. Interview by Asher Mullard.
    Brown P
    Nat Rev Drug Discov; 2011 Sep; 10(10):726. PubMed ID: 21959279
    [No Abstract]   [Full Text] [Related]  

  • 32. The long and winding road.
    Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946
    [No Abstract]   [Full Text] [Related]  

  • 33. Marc Kirschner. Interview by Asher Mullard.
    Kirschner M
    Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
    [No Abstract]   [Full Text] [Related]  

  • 34. New working paradigms in research laboratories.
    Keighley W; Sewing A
    Drug Discov Today; 2009 Jul; 14(13-14):625-9. PubMed ID: 19477291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmodium: drug discovery and development--an industrial perspective.
    Ridley RG
    Exp Parasitol; 1997 Nov; 87(3):293-304. PubMed ID: 9371097
    [No Abstract]   [Full Text] [Related]  

  • 36. An audience with... Jan M. Lundberg.
    Lundberg JM
    Nat Rev Drug Discov; 2005 Jun; 4(6):452. PubMed ID: 15959949
    [No Abstract]   [Full Text] [Related]  

  • 37. Open innovation: share or die..
    Talaga P
    Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 39. The FDA and safety--beyond the heparin crisis.
    Laurencin CT; Nair L
    Nat Biotechnol; 2008 Jun; 26(6):621-3. PubMed ID: 18536680
    [No Abstract]   [Full Text] [Related]  

  • 40. Niche drugs aren't a cheap alternative to blockbusters.
    Tracey WR
    Nature; 2007 Feb; 445(7130):818. PubMed ID: 17314952
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.